So far, pharmacotherapies used to treat T2D include metformin, insulin, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists (28–31). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.